A class action lawsuit has been filed against Park Ha Biological Technology, accusing the company and some executives of securities fraud through a pump-and-dump scheme. The complaint claims Park Ha's stock price was artificially inflated from $4.00 at IPO to $41.49 via fraudulent promotions and impersonation of financial advisors on social media. This manipulation led to a market collapse, harming investors. The case is open for investors to join as Lead Plaintiff until September 28, 2026.
Park Ha Biological Technology lawsuit news is presented with Pluang's health sector data for context. For readers following health stocks, 59 of 91 US health-sector stocks rose and 31 fell today. Notable movers include NVAX at USD 10.17 with +8.77% change and 100% buy order activity, TXG at USD 78.51 with +8.02% change and balanced buy/sell activity, and SANA at USD 3.12 with +6.85% change and 86% sell order activity, as of Sep 17, 2026 21:11 WIB.
In Q3 2026, websites on Cloudflare's network blocked 13.47% of AI crawler requests, more than double the 5.98% blocked a year earlier. This rise in access denial affects how brands appear in AI-generated answers from platforms like ChatGPT, Gemini, a...
JPMorgan Asset Management (Canada) announced the final cash distributions for September 2026 for three of its ETFs traded on the Toronto Stock Exchange. Unitholders of record on October 19, 2026, will receive payments on October 23, 2026. The ETFs an...
Stillwater Critical Minerals Corp. has upgraded to the OTCQX Best Market from the OTCQB Venture Market, beginning trading under the symbol "PGEZF." This move enhances the company's visibility, liquidity, and accessibility to U.S. investors as it adva...
WasabiCard, a stablecoin-based global payment provider, engaged in key partnership discussions at TOKEN2049 Singapore 2026, focusing on white-label card issuing, global payouts, and embedded payments. The company highlighted growing demand in APAC fo...
The global next generation antibody therapeutics market is projected to increase from $5.45 billion in 2026 to $5.76 billion by 2035, growing at a CAGR of 1%. Growth is fueled by advances in biotechnology, rising demand for targeted therapies, and in...
